Study of Aritinercept in Patients With Generalized Myasthenia Gravis
ConditionMyasthenia Gravis, Generalized
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-85
SponsorAurinia Pharmaceuticals Inc.
About this trial
This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.
Eligibility criteria
Qualifiers
Adult patients (18-85 years old)
Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG
Additional inclusion criteria are defined in the protocol
Disqualifiers
Current or medical history of malignancy within the last 5 years
Pregnant, breastfeeding or intending to become pregnant during the Study
Additional exclusion criteria are defined in the protocol
Trial design
Treatments tested in this trial
- Aritinercept
- Placebo
Treatment groups
81 Participants
are divided into 2 treatment groupsLocations
3Aurinia Investigational Site32714, Altamonte SpringsFlorida, United States
Aurinia Investigational Site33487, Boca RatonFlorida, United States
Aurinia Investigational Site33173, MiamiFlorida, United States
Sponsors and collaborators
Aurinia Pharmaceuticals Inc.
Lead sponsor
Source ClinicalTrials.gov